Clinical Trials
9 trialsNCT01366144 2026-04-13
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT07423078 2026-04-13
WOLF
University of Pittsburgh
Phase 2 Recruiting
NCT05010629 2025-05-31
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04999761 2024-09-25
AB122 Platform Study
Taiho Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT04832438 2022-02-22
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma
Actuate Therapeutics Inc.
Phase 2 Withdrawn
NCT02658214 2020-08-20
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
AstraZeneca
Phase 1 Completed
NCT02124707 2020-08-12
Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT03637335 2018-08-20
METAXIOM
Institut Cancerologie de l'Ouest
Phase 3 Terminated
NCT01166542 2014-11-05
Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers
Oncolytics Biotech
Phase 3 Completed